Abstract
We estimated (1) the time from first detectable virus to peak viral concentration (proliferation time), (2) the time from peak viral concentration to initial return to the limit of detection (clearance time), and (3) the peak viral concentration separately for 69 individuals infected with SARS-CoV-2 variants alpha (n=14), epsilon (n=10), and non-variants of interest/variants of concern (VOI/VOCs) (n=45). For individuals infected with alpha, the mean duration of the proliferation phase was 4.3 days (95% credible interval [3.0, 6.0]), the mean duration of the clearance phase was 7.4 days [6.0, 9.0], and the mean overall duration of infection (proliferation plus clearance) was 11.7 days [9.8, 13.8]. For individuals infected with epsilon, the mean duration of the proliferation phase was 5.6 days [4.0, 7.4], the mean duration of the clearance phase was 8.6 days [6.7, 10.6], and the mean overall duration of infection was 14.2 days [11.8, 16.7]. These compare to a mean proliferation phase of 4.3 days [3.4, 5.4], a mean clearance phase of 6.9 days [6.0, 7.9], and a mean duration of infection of 11.3 days [10.1, 12.5] for non-VOI/VOC infections. The peak viral concentration was 20.9 Ct [18.3, 23.5] for alpha, 20.6 Ct [17.8, 23.5] for epsilon, and 20.8 Ct [19.1, 22.4] for VOI/VOCs. This converts to 7.9 log10 RNA copies/ml [7.2, 8.7] for alpha, 8.0 log10 RNA copies/ml [7.2, 8.8] for epsilon, and 8.0 log10 RNA copies/ml [7.5, 8.4] for non-VOI/VOCs. The distributions of individual-level means are suggestive of longer clearance times for the VOCs. The overall durations of acute infection varied widely across individuals, with individual posterior mean acute infection durations ranging from 5.5 - 16.1 days for alpha, 9.4 - 20.3 days for epsilon, and 4.8 - 17.6 days for non-VOI/VOCs. These data offer evidence that infections with SARS-CoV-2 variants alpha and epsilon feature broadly similar viral trajectories as infections with non-VOI/VOCs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Huffman Family Donor Advised Fund (NDG); Fast Grant funding from the Emergent Ventures at 85 the Mercatus Center; George Mason University (NDG); the Morris-Singer Fund for the Center for 86 Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health (YHG).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Residual de-identified viral transport media from anterior nares and oropharyngeal swabs collected from players, staff, vendors, and associated household members from a professional sports league were obtained from BioReference Laboratories. In accordance with the guidelines of the Yale Human Investigations Committee, this work with de-identified samples was approved for research not involving human subjects by the Yale Internal Review Board (HIC protocol # 2000028599). This project was designated exempt by the Harvard IRB (IRB20-1407).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† denotes co-senior authorship
Larger sample size, inclusion of additional SARS-CoV-2 variant, addition of coauthors who assisted with sequencing.
Data Availability
Data and code are available online at https://github.com/gradlab/CtTrajectories_AllVariants
